

TABLE OF CONTENTS

PART I: INTRODUCTION TO THE PSYCHOPHARMACOLOGY CURRICULUM FOR TEACHERS OF MEDICAL STUDENTS AND PRIMARY CARE PHYSICIANS

GUIDELINES AND INSTRUCTIONS FOR USE	6
Background, Objectives, and Rationale	6
Use of Lecture Modules	8
Getting Help	8
OVERVIEW AND EDUCATIONAL OBJECTIVES	9
Knowledge	9
Skills	9
TIPS ON CONTENT AND PEDAGOGY	10
Special Considerations Related to Lectures	11
ACKNOWLEDGEMENTS	12
CONTRIBUTORS	12

PART II: INTRODUCTION TO THE PSYCHOPHARMACOLOGY CURRICULUM FOR TEACHING MEDICAL STUDENTS

PREFACE	15
RATIONALE	16
ORGANIZATION OF A PSYCHOPHARMACOLOGY PROGRAM WITHIN A MEDICAL STUDENT PROGRAM	17
OVERVIEW AND EDUCATIONAL OBJECTIVES	18
Knowledge	18
Skills	18
TIPS ON CONTENT AND PEDAGOGY	19
Special Considerations Related to Lectures	20
Issues, Concepts, and a Template	21
Material on Psychosocial Topics	24
Supervision	26
Reading Materials	26
DOING AN EVALUATION	27

APPENDICES

APPENDIX A: Excerpted from ADMSEP Clinical Learning Objectives Psychiatry Education of Medical Students (Introduction on Psychopharmacology)	28
---	----

APPENDIX B: Outline of The Stanford Psychiatry Core Clerkship Objectives.....35

APPENDIX C: Overview Articles on Psychopharmacology Practice.....40

APPENDIX D: Reading Materials50

APPENDIX E: Computers and Psychopharmacology.....54

PART III: LECTURES

CORE LECTURES

Child and Adolescent Psychopharmacology

Pediatric Psychopharmacology1.1 – 1.66
Vishal Madaan, M.D., Christopher J. Kratochvil, M.D., Robert McKelvey, M.D.

Attention Deficit Hyperactivity Disorder Child/Adolescent/Adult2.1 – 2.82
Daniel Orr, M.D.

Schizophrenia

“Psychosis” in Medical Practice3.1 – 3.43
Po W. Wang, M.D.

Mid and Long-Term Efficacy of Antipsychotic Medications for Schizophrenia.....4.1 – 4.70
Ira Glick, M.D.

Bipolar Disorders.....5.1 – 5.75

Po Wang, M.D.

Depression.....6.1 – 6.96

Eric Peselow, M.D., Daniel G. Orr, M.D.

Anxiety

Anxiety Disorders: GAD7.1 – 7.64
Daniel G. Orr, M.D.

Anti-Anxiety Agents8.1 – 8.54
Thomas J. Raedler, M.D., Robert H. Howland, M.D.

PTSD.....9.1 – 9.76

Howard Fenn, M.D., Thomas A. Mellman, M.D., Daniel G. Orr, M.D.

Eating Disorders.....10.1 – 10.59

B. Timothy Walsh, M.D., Lawrence Cohen, Pharm.D.

Sleep Disorders11.1 – 11.60
Lawrence Adler, M.D.

Substance Abuse Disorders.....12.1 – 12.66
Po Wang, M.D.

Managing Neurocognitive Behavioral Symptoms in Patients with Major Neurocognitive Disorders13.1 – 13.100
James Ellison, M.D.

Psychotropic Medications During Pregnancy and Postpartum14.1 – 14.67
Marlene P. Freeman, M.D., Bradley Gaynes, M.D., Laura J Miller, M.D.

Geriatric Psychopharmacology15.1 – 15.27
Linda Farho, Pharm. D., Lawrence Adler, M.D.

Suicide.....16.1 – 16.32
John Mann, M.D., Lawrence Adler, M.D.

CLINICAL PEARLS

Art of Psychopharmacology.....17.1 – 17.14
Ira D. Glick, M.D., Richard Balon, M.D., Eric Peselow, M.D., Robert Howland, M.D.

Therapeutic Alliance in Pediatric Psychopharmacology.....18.1 – 18.42
Shashank V. Joshi, M.D.

Evaluating and Managing Side Effects of Psychiatric Medications19.1 – 19.27
Joseph F. Goldberg, M.D., Robert Howland, M.D.

Psychopharmacology: “Warnings” and Management20.1 – 20.64
Daniel G. Orr, M.D.

AN OPTIONAL COURSE ON SUBSTANCE ABUSE

For medical student and primary care physician educators, these lectures have been reviewed and updated by Professor Charles P. O’Brien. He notes that the biggest news is the opioid epidemic. This was influenced by the concern about not neglecting pain as an important symptom. We started teaching doctors about the safety and benefits of prescription opioids. At least on pharma company aggressively (“allegedly”) marketed their product as having low addiction risk. Medical students and residents received very little training on the proper way to prescribe opioids and how to treat pain in a multi-disciplinary program. Also, supplies of opioids leaked out to the street market. Not only did the abuse of opioids increase, but it fueled heroin use which was usually cheaper than prescription opioids.

Students should be taught the risks and benefits of opioids, the non-opioid methods to treat pain, the opioid addiction medications in combination with counseling/psychotherapy. Important medications include methadone, buprenorphine (Suboxone), naltrexone and extended release naltrexone (Vivitrol) and naloxone (Narcan) for overdose.

We have summarized the entire course in two lectures, reviewed and compiled by Mujeeb Shad, M.D. Teachers may use the two lectures OR the entire 14 lecture series.

Summary Lectures

Psychopharmacology of Addiction21.1 – 21.64
Charles P. O’Brien, M.D., Ph.D., Mujeeb Shad, M.D.

Neurobiology Addictions: Part I and II.....22.1 – 22.111
Charles P. O’Brien, M.D., Ph.D., Mujeeb Shad, M.D.

Full Course Lectures

Addiction: A Disease of the Brain23.1 – 23.49
Charles P. O’Brien, M.D., Ph.D.

Substance Abuse: The Nation’s Number One Health Problem24.1 – 24.31
James Cornish, M.D.

Cannabis.....25.1 – 25.45
Charles P. O’Brien, M.D., Ph.D., John T. Pichot, M.D.

Hallucinogens26.1 – 26.54
Benoit Dubé, M.D.

Prescription Drug Abuse.....27.1 – 27.44
Kyle M. Kampman, M.D.

Psychiatric Disorders and Psychotherapy of Substance Abuse.....28.1 – 28.51
Robert M. Weinrieb, M.D.

Effects of Drugs on the Developing Brain: Pregnancy, Adolescence and Beyond.....29.1 – 29.40
Marina Goldman, M.D.

Medical Complications of Substance Abuse30.1 – 30.105
Phil Green, M.D.

Genetics of Substance Abuse and Neuropharmacology of Opiates.....31.1 – 31.57
Wade Berrettini, M.D.

Genetics of Addiction.....32.1 – 32.50
Wade Berrettini, M.D.

Neurobiology of Addiction.....33.1 – 33.40
Charles P. O’Brien, M.D., Ph.D.

Cocaine and Stimulants.....34.1 – 34.42
Kyle M. Kampman, M.D.

Nicotine Dependence.....35.1 – 35.45
Henry R. Kranzler, M.D.

Alcohol Dependence.....36.1 – 36.56
Henry R. Kranzler, M.D.